In addition to the listed reports, CAR-T cell therapy based on the targeting tumor-associated glycoprotein (TAG)-72 in colorectal cancer [98], carcinoembryonic antigen (CEA) in lung cancer [99] and liver cancer [100], mesothelin [101], and EGFR [102] in pancreatic cancer, fibroblast activation protein (FAP) in mesothelioma [103], IL13Rα2 in glioblastoma [104], and mucin-1 (MUC1) in seminal vesicle cancer [105] have been conducted or are ongoing to address the safety and efficacy of redirected effector T cells in patients with tumors. The gene discussed is MUC1; the disease is glioblastoma.